0NWK Stock Chart & Stats
€0.06
€0.00(0.00%)
At close: 4:00 PM EST
€0.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.07 - €0.98
Previous CloseN/A
Volume0.00
Average Volume (3M)4.85K
Market Cap
€245.27M
Enterprise Value€77.01T
Total Cash (Recent Filing)€656.00K
Total Debt (Recent Filing)€12.84M
Price to Earnings (P/E)―
Beta0.91
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding587,615,970
10 Day Avg. Volume6,235
30 Day Avg. Volume4,854
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe sharp 2025 revenue rebound indicates improving activity across Valerio Therapeutics’ development programs after a stagnant prior year. If maintained, stronger revenue can support research investment, improve operating leverage, and provide a more durable base for future partnering or financing opportunities.
Gross MarginSustained gross margins of roughly 67–71% are favorable for a clinical-stage biotechnology model because incremental development-related revenue can retain meaningful contribution after direct costs. Maintaining this profile would improve the economics of future collaborations, licensing income, or eventual product commercialization.
Cash Flow ImprovementThe return to positive operating and free cash flow in 2025 marks a meaningful improvement from several years of sizable cash burn. Although not yet proven consistent, internally generated cash can reduce near-term dependence on external financing and help fund ongoing oncology research activities.
Bears Say
Persistent Net LossesValerio Therapeutics remains loss-making despite the 2025 revenue improvement, showing that current activities have not yet produced consistent earnings power. Continued net losses can consume capital, limit financial resilience, and require additional funding before oncology programs generate substantial partnering or commercial returns.
High LeverageDebt materially exceeds the company’s equity base, leaving Valerio Therapeutics with constrained financial flexibility. Elevated leverage can increase financing pressure, reduce room to absorb setbacks in clinical development, and make it harder to allocate capital between research programs and balance-sheet needs over the next several quarters.
Volatile Cash GenerationThe 2025 cash-flow improvement has not yet demonstrated durability because free cash flow was highly volatile and fell sharply versus the preceding period as reported. A return to heavier research spending or renewed cash burn could therefore recreate dependence on equity issuance or other external financing.
Valerio Therapeutics News
0NWK FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest share price was €0.07 and its highest was €0.98 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €245.27M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 587,615,970 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in GB:0NWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―